Skip to main content

Advertisement

Table 2 Meta-analysis of the association between each XPD gene polymorphism and NHL risk

From: Association of the Asp312Asn and Lys751Gln polymorphisms in the XPD gene with the risk of non-Hodgkin’s lymphoma: evidence from a meta-analysis

Variable No. of studies Sample size (cases/controls) Homozygous Heterozygous Recessive Dominant Allele comparison
OR (95% CI) P het OR (95% CI) P het OR (95% CI) P het OR (95% CI) P het OR (95% CI) P het
Asp312Asn polymorphism AA vs. GG GA vs. GG AA vs. (GA + GG) (GA + AA) vs. GG A vs. G
All 6 3,095/3,306 1.11 (0.94-1.32) 0.718 1.00 (0.89-1.11) 0.935 1.12 (0.95-1.31) 0.368 1.02 (0.92-1.13) 0.426 1.04 (0.96-1.12) 0.717
Ethnicity
Caucasian 3 1,596/1,833 1.10 (0.88-1.37) 0.580 1.00 (0.87-1.16) 0.073 1.09 (0.89-1.34) 0.156 1.02 (0.89-1.17) 0.315 1.03 (0.93-1.14) 0.986
Asian 1 307/303 1.38 (0.31-6.23) NA 1.39 (0.87-2.22) NA 1.32 (0.29-5.95) NA 1.39 (0.88-2.19) NA 1.36 (0.89-2.07) NA
Mixed 2 1,192/1,170 1.12 (0.86-1.46) 0.192 0.94 (0.79-1.12) 0.687 1.16 (0.90-1.50) 0.217 0.98 (0.83-1.15) 0.450 1.02 (0.90-1.15) 0.267
Source of the controls
PB 5 2,788/3,003 1.11 (0.94-1.32) 0.591 0.98 (0.88-1.09) 0.223 1.12 (0.95-1.31) 0.252 1.00 (0.91-1.12) 0.549 1.03 (0.95-1.11) 0.864
HB 1 307/303 1.38 (0.31-6.23) NA 1.39 (0.87-1.22) NA 1.32 (0.29-5.95) NA 1.39 (0.88-2.19) NA 1.36 (0.89-2.07) NA
NHL subtype
DLBCL 4 726/2,170 1.00 (0.73-1.37) 0.829 0.98 (0.80-1.18) 0.667 1.01 (0.75-1.37) 0.669 1.02 (0.86-1.22) 0.463 0.99 (0.86-1.14) 0.998
FL 5 1,088/2,772 1.12 (0.88-1.42) 0.595 1.00 (0.85-1.17) 0.059 1.10 (0.88-1.38) 0.194 1.03 (0.89-1.20) 0.297 1.04 (0.93-1.16) 0.732
Lys751Gln polymorphism CC vs. AA AC vs. AA C/C vs. (AC + AA) (AC + CC) vs. AA C vs. A
All 7 3,249/3,676 0.97 (0.83-1.15) 0.428 0.96 (0.86-1.06) 0.184 1.00 (0.86-1.16) 0.200 0.96 (0.87-1.06) 0.335 0.98 (0.91-1.05) 0.405
Ethnicity
Caucasian 3 1,666/1,848 0.88 (0.72-1.09) 0.305 0.99 (0.86-1.14) 0.255 0.88 (0.72-1.07) 0.137 0.96 (0.84-1.10) 0.482 0.95 (0.86-1.05) 0.522
Asian 2 381/659 1.85 (0.53-6.47) 0.823 1.15 (0.76-1.73) 0.159 1.81 (0.52-6.33) 0.777 1.20 (0.81-1.78) 0.184 1.23 (0.85-1.77) 0.232
Mixed 2 1,202/1,169 1.11 (0.85-1.44) 0.397 0.88 (0.74-1.05) 0.140 1.19 (0.93-1.52) 0.718 0.93 (0.79-1.09) 0.140 1.00 (0.89-1.13) 0.227
Source of the controls
PB 5 2,868/3,017 0.96 (0.82-1.13) 0.307 0.94 (0.84-1.05) 0.205 0.99 (0.85-1.15) 0.111 0.95 (0.85-1.05) 0.438 0.97 (0.90-1.04) 0.530
HB 2 381/659 1.85 (0.53-6.47) 0.823 1.15 (0.76-1.73) 0.159 1.81 (0.52-6.33) 0.777 1.20 (0.81-1.78) 0.184 1.23 (0.85-1.77) 0.232
NHL subtype
DLBCL 5 946/2,731 0.96 (0.74-1.24) 0.003 0.90 (0.76-1.07) 0.213 1.01 (0.79-1.29) 0.005 0.95 (0.81-1.11) 0.042 0.96 (0.85-1.08) 0.005
FL 6 1,227/3,322 0.87 (0.69-1.08) 0.522 0.95 (0.82-1.11) 0.234 0.88 (0.72-1.09) 0.227 0.95 (0.82-1.09) 0.448 0.93 (0.84-1.03) 0.681
  1. OR, odds ratio; CI, confidence interval; P het, P value for heterogeneity; NA, not applicable; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma. Other abbreviations as in Table 1.